Cost-effectiveness of strict "get to goal" treatment directives in the treatment of younger patients with newly diagnosed type 2 diabetes mellitus (T2DM)

被引：0
|
作者：
Willis, M. [1 ]
Borg, S. [1 ]
Persson, U. [1 ]
Neslusan, C. [2 ]
机构：
[1] Swedish Inst Hlth Econ, IHE, Lund, Sweden
[2] Johnson & Johnson, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64969-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [2] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [3] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
  • [4] THE COST-EFFECTIVENESS OF GETTING TO GLUCOSE, BLOOD PRESSURE, AND LIPID GOALS IN PATIENTS NEWLY DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM) AND YOUNGER THAN FIFTY IN SWEDEN
    He, J.
    Neslusan, C.
    Willis, M.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2011, 14 (07) : A479 - A479
  • [5] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
  • [6] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [7] The Cost-Effectiveness of "Getting to Goal" in Patients with Newly Diagnosed Type 2 Diabetes
    Willis, Michael
    Asseberg, Christian
    He, Jianming
    Neslusan, Cheryl
    DIABETES, 2009, 58 : A45 - A45
  • [8] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [9] Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
    Priyadi, Akhmad
    Permana, Hikmat
    Muhtadi, Ahmad
    Sumiwi, Sri A.
    Sinuraya, Rano K.
    Suwantika, Auliya A.
    HEALTHCARE, 2021, 9 (02)
  • [10] Reasons for Non-Treatment of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in the United Kingdom
    Marrett, Elizabeth
    Jameson, Kevin
    Zhang, Qiaoyi
    Meiler, Susanne
    Radican, Larry
    Sinclair, Alan
    DIABETES, 2010, 59 : A293 - A294
12345